NLRP3 and arthritic joint disease: Therefore, NLRP3 could became a valid biomarker of ipilimumab-induced cardiotoxicity under hypoglycemia; pharmacological inhibition of NLRP3, through clinically available drugs [90,93], safe in humans, currently studied for therapy of acute gout and arthritis could be an effective therapeutic strategy aimed at improving anticancer responsiveness to ipilimumab and reducing its cardiovascular side effects.